| Literature DB >> 29237387 |
Franco Grimaldi1, Nicola Fazio2, Roberto Attanasio3, Andrea Frasoldati4, Enrico Papini5, Nadia Cremonini6, Maria V Davi7, Luigi Funicelli8, Sara Massironi9, Francesca Spada2, Vincenzo Toscano10, Annibale Versari11, Michele Zini4, Massimo Falconi12, Kjell Oberg13.
Abstract
Well-established criteria for evaluating the response to treatment and the appropriate followup of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: NEN; NET follow-up; Neuroendocrine tumors; carcinoidzzm321990syndrome; criteria of response; gastrinoma; imaging; insulinoma; markers; non-functioning NET.
Mesh:
Substances:
Year: 2018 PMID: 29237387 DOI: 10.2174/1871530318666171213145803
Source DB: PubMed Journal: Endocr Metab Immune Disord Drug Targets ISSN: 1871-5303 Impact factor: 2.895